Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kintor PharmaceuticalKNTPF 29 3-Year EBITDA Growth Rate is 47.10% as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 1,130 Biotechnology companies, Kintor Pharmaceutical ranks better than 83.81% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 47.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kintor Pharmaceutical was 51.90% per year. The lowest was -108.60% per year. And the median was -11.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Kintor Pharmaceutical 3-Year EBITDA Growth Rate Related Terms
KNTPF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Kintor Pharmaceutical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 47.10% mean?
Kintor Pharmaceutical (KNTPF) has a 3-Year EBITDA Growth Rate of 47.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kintor Pharmaceutical and its competitors. According to the industry distribution chart, Kintor Pharmaceutical ranks #183 out of 1130 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Kintor Pharmaceutical's 3-Year EBITDA Growth Rate too high?
Kintor Pharmaceutical's current 3-Year EBITDA Growth Rate is 47.10%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Kintor Pharmaceutical's value of 47.10% is 217.2% above this industry median. Based on the distribution chart, Kintor Pharmaceutical ranks #183 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kintor Pharmaceutical has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #183 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Kintor Pharmaceutical in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Kintor Pharmaceutical's value of 47.10% is 217.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kintor Pharmaceutical's current 3-Year EBITDA Growth Rate of 47.10% is 217.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kintor Pharmaceutical and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kintor Pharmaceutical's current 3-Year EBITDA Growth Rate is 47.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current 3-Year EBITDA Growth Rate of 47.10%. The current 3-Year EBITDA Growth Rate is 47.10% and 217.2% above the Biotechnology industry median of 14.85. Kintor Pharmaceutical's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current 3-Year EBITDA Growth Rate is 47.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
29GF Score
Get the complete analysis for KNTPF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
